MARKET

ZYNE

ZYNE

Zynerba Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.230
-0.020
-0.62%
Closed 17:40 09/24 EDT
OPEN
3.250
PREV CLOSE
3.250
HIGH
3.300
LOW
3.160
VOLUME
467.48K
TURNOVER
--
52 WEEK HIGH
8.83
52 WEEK LOW
2.550
MARKET CAP
94.49M
P/E (TTM)
-1.7441
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Zynerba Pharmaceuticals - Whether They've Cracked The Code For Fully Methylated FX Syndrome Patients
Pivotal results from Phase 3 clinical trials of Zygel for the treatment of FX Syndrome didn’t meet endpoints, but a significant discovery was made.Pre-planned ad hoc analysis of the trials showed that Zygel achieved Statistical Significance in a specific type of FX Syndrome that involves a fully methylated FMR1 Gene.Underlying data on the efficacy of Zygel for the acute form of FX Syndrome is promising with a P-value of 0.02 on the Primary Endpoint.FDA discussions for approval of NDA (New Drug Application) based on the ad hoc analysis are scheduled in Q4 2020, and results come out in the same quarter.Good reasons to believe that there's a high chance of positive news from the FDA meeting this quarter.
Seekingalpha · 14h ago
We're Keeping An Eye On Zynerba Pharmaceuticals' (NASDAQ:ZYNE) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Simply Wall St. · 1d ago
Zynerba Pharmaceuticals (ZYNE) Investor Presentation - Slideshow
The following slide deck was published by Zynerba Pharmaceuticals, Inc. in conjunction with this event.
Seekingalpha · 6d ago
Zynerba Pharmaceuticals (ZYNE) Jumps: Stock Rises 7.7%
Zynerba Pharmaceuticals (ZYNE) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Zacks · 6d ago
Making The Case For Zynerba Pharmaceuticals
Zynerba's Pivotal Phase 3 CONNECT-FX study is the first placebo-controlled study to show statistical significance in children with Fragile X Syndrome (FXS) to date - a significant accomplishment.The stock was hammered because Zynerba missed the primary and secondary endpoints. However, a pre-planned ad hoc analysis tells a different story in patients with full methylation of the FMR1 gene.Zynerba's case that Zygel should be approved for the treatment of FXS in children with full methylation of the FMR1 gene is strong for an abundance of reasons.
Seekingalpha · 09/17 23:10
Zynerba Pharmaceuticals Receives Orphan Drug Designation for Cannabidiol for the Treatment of 22q11.2 Deletion Syndrome
DEVON, Pa., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that the U.S. Food and Drug Administration has granted orphan
GlobeNewswire · 09/17 18:55
Zynerba's cannabidiol an Orphan drug for a rare chromosomal disorder
The FDA has granted Orphan drug status for Zynerba's ([[ZYNE]] +6.2%) cannabidiol as a treatment of 22q.11.2 deletion syndrome, according to a post to the agency's website.Also known as DiGeorge syndrome,
Seekingalpha · 09/17 17:49
Zynerba Pharmaceuticals Provides Update on Recent Milestones
\- Meeting with the U.S. Food and Drug Administration (FDA) Planned for 4Q2020 to Discuss the Regulatory Path Forward for Zygel™ in Children and Adolescents with Fragile X Syndrome and a Fully Methylated FMR1 Gene -\- Newly Issued FXS Patent Supplements Intellectual Property Protection –\
GlobeNewswire · 09/14 11:55
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ZYNE. Analyze the recent business situations of Zynerba Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ZYNE stock price target is 10.00 with a high estimate of 15.00 and a low estimate of 4.500.
EPS
Institutional Holdings
Institutions: 122
Institutional Holdings: 7.78M
% Owned: 26.58%
Shares Outstanding: 29.26M
TypeInstitutionsShares
Increased
18
451.83K
New
51
761.96K
Decreased
20
2.82M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.88%
Pharmaceuticals & Medical Research
-0.82%
Key Executives
Chairman/Chief Executive Officer/Director
Armando Anido
President
Terri Sebree
Chief Financial Officer/Vice President
James Fickenscher
Vice President/General Counsel/Secretary
Suzanne Hanlon
Vice President
Brian Rosenberger
Vice President/Director of Investor Relations
William Roberts
Lead Director/Independent Director
Warren Cooper
Independent Director
John Butler
Independent Director
William Federici
Other
Liza Squires
Independent Director
Daniel Kisner
Independent Director
Kenneth Moch
Independent Director
Pamela Stephenson
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ZYNE
Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which is a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system. ZYN002 is in Phase II clinical development in patients with refractory epilepsy, in patients with osteoarthritis of the knee, as well as in patients with Fragile X syndrome. ZYN001 is a pro-drug of tetrahydrocannabinol (THC) that enables transdermal delivery through the skin and into the circulatory system through a patch. ZYN001 is targeting two pain indications, fibromyalgia and peripheral neuropathic pain.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Zynerba Pharmaceuticals Inc stock information, including NASDAQ:ZYNE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ZYNE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ZYNE stock methods without spending real money on the virtual paper trading platform.